CRBU (Caribou Biosciences) Notes Receivable: $0.00 Mil (As of Mar. 2026)


CRBU Caribou Biosciences Inc CRBU
64 GF Score
Price $1.93
GF Value $1.69
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Notes Receivable?

Caribou Biosciences CRBU +1.04% 64 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates CRBU with a GF Score™ of 64/100 and a GF Value™ of $1.69 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Caribou Biosciences's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Caribou Biosciences Notes Receivable Related Terms

Caribou Biosciences Notes Receivable Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Notes Receivable Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Caribou Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CRBU
64GF Score
Caribou Biosciences Inc CRBU
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Caribou Biosciences (CRBU) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Caribou Biosciences and its competitors.
Is Caribou Biosciences' Notes Receivable too high?
Caribou Biosciences' current Notes Receivable is $0.00 Mil. Overall, Caribou Biosciences has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Notes Receivable compare to YDES and PRQR?
Caribou Biosciences' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.69, compared to a current price of $1.93 — trading 14.2% above its estimated fair value. The current Notes Receivable is $0.00 Mil. Caribou Biosciences' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued. The current stock price of $1.93 is trading 14.2% above its estimated GF Value™ of $1.69. GuruFocus considers Caribou Biosciences to be Modestly Overvalued.

Key valuation signals for CRBU:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $1.69 vs. price of $1.93 (14.2% above fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
64GF Score

Get the complete analysis for CRBU

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.69
GF Value